Stockpolly
Search
BLTE · NASDAQ · Biotechnology

Belite Bio (ADR) (BLTE)

Develops oral investigational therapies for retinal and metabolic diseases.

$163.00
Pre-market+1.55 (+0.96%)
At close$161.45(+3.03%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24May 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
1178101011161823283335
Research & development95797791110151618
2221346713131717
General & administrative222134671313170
Operating income−11−7−8−10−10−11−16−18−23−28−33−35
000111111367
Other non-operating income000−1−1−4−1−1−13−60
Income before tax−11−7−8−9−9−10−14−16−22−25−27−28
Income tax expense000000000000
Net income from continuing operations−11−7−8−9−9−10−14−16−22−25−27−28
Net income−11−7−8−9−9−10−14−16−22−25−27−28
EPS, basic−$0.40−$0.25−$0.27−$0.31−$0.28−$0.32−$0.44−$0.50−$0.65−$0.72−$0.68−$0.71
EPS, diluted−$0.40−$0.25−$0.27−$0.31−$0.28−$0.32−$0.44−$0.50−$0.65−$0.72−$0.68−$0.71
Weighted average shares, basic272830303131323333344040
Weighted average shares, diluted272830303131323333344040
EBITDA−11−7−8−9−9−8−14−16−22−31−27−35
Depreciation & amortization000000000000
EBIT−11−7−8−9−9−8−14−16−22−31−27−35